Vice President, Platform Technologies

Morgan is Vice President, Platform Technologies at Chroma Medicine. Prior to joining Chroma, she spent 2 years as a consultant to Third Rock Ventures helping to launch Faze Medicines. Previously, she spent 5 years at Editas Medicine, where she was the founding scientist, and where she led the preclinical development of EDIT-101, the first in vivo use of a CRISPR genome editing medicine. Morgan received a B.A. in Cell and Molecular Biology from Connecticut College and a Ph.D in Genetics from Harvard University, where she worked to develop gene editing technologies in the lab of J. Keith Joung, M.D., Ph.D., at Massachusetts General Hospital.